Lack of uniformity among United States recommendations for diagnosis and management of acute, uncomplicated cystitis
Introduction and hypothesis
Acute, uncomplicated cystitis is one of the most common bacterial infections seen in clinical practice. Quality improvement and antibiotic stewardship efforts to optimize cystitis management rely on clinicians managing patients in a manner recommended by experts and guidelines. However, it is unclear if recent recommendations for cystitis from experts and guidelines from US medical societies that provide recommendations are well aligned.
We examined recommendations and guidelines for acute, symptomatic cystitis in women published in US medical societies’ journals from January 1, 2008, to December 31, 2016, within the fields of family medicine, obstetrics and gynecology, internal medicine, female pelvic medicine and reconstructive surgery, and infectious diseases.
All recommendations endorsed the use of symptoms and urine dipstick to diagnose cystitis. Some societies did not recommend urine dipstick in patients with recurrent urinary tract infection (UTI), classic UTI symptoms, or a lack of underlying conditions or competing diagnoses. All endorsed nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin as first-line agents. Some guidelines classified fluoroquinolones as second- or third-line, while others considered them first-line treatment for UTI. Avoiding use of amoxicillin and ampicillin, antibiotic agents with high prevalence of resistance in the US, was recommended by some societies.
US recommendations differed in their approach to the treatment of acute, uncomplicated cystitis. Lack of uniformity likely contributes to clinical management variance for patients with UTI and hampers quality improvement and antibiotic stewardship efforts aimed at promoting optimal management. Our findings emphasize the need for more consistent recommendations for cystitis management.
KeywordsAntimicrobial treatment Diagnosis Management Recommendations Urinary tract infection
Compliance with ethical standards
Conflicts of interest
Dr. David A. Haake owns shares in MicrobeDx, Inc., and Qvella, Inc. Dr. Loren G. Miller has received grants from Achaogen, Merck, and Tetraphase.
- 1.Schappert S, Rechtsteiner E. Ambulatory medical care utilization estimates for 2007. Vital and Health Statistics. Series 13, Data from the National Health Survey. 2011(169): p. 1–38.Google Scholar
- 10.Bulletins, A.C.o.P., Sheffield J. Treatment of urinary tract infections in nonpregnant women. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists, 2008/2016(91).Google Scholar
- 11.Gupta K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.CrossRefPubMedGoogle Scholar
- 16.Bernstein D. Clinical guideline review: acute uncomplicated cystitis. ACEP Now; 2012.Google Scholar
- 17.Badalato G, Kaufmann M. Adult UTI. American Urological Association: Medical Student Education; 2016.Google Scholar
- 20.FDA, US FDA updates warnings for fluoroquinolone antibiotics; 2016.Google Scholar
- 21.American Urologic Association: Don’t treat uncomplicated cystitis in women with fluoroquinolones if other oral antibiotic treatment options exist. Choosing Wisely 2017 [cited 2018].Google Scholar